Statistical Evaluation of the Effect of Gemfibrosil, a Cholesterol Reducing Drug, on Some Biochemical Coronary Heart Disease Risk Variables
| Autor: | K. Chwistecki, Anna Bartkowiak, S. Łsukasik |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Statistics and Probability
Drug medicine.medical_specialty business.industry Cholesterol media_common.quotation_subject General Medicine Coronary heart disease chemistry.chemical_compound High-density lipoprotein chemistry Gemfibrosil Internal medicine Regression toward the mean Medicine Uric acid Gemfibrozil lipids (amino acids peptides and proteins) Statistics Probability and Uncertainty business media_common medicine.drug |
| Zdroj: | Biometrical Journal. 33:711-718 |
| ISSN: | 1521-4036 0323-3847 |
| DOI: | 10.1002/bimj.4710330612 |
| Popis: | The evaluation is based on the clinic trial with gemfibrosil (“Gevilon”, Parke-Davis) carried out in a group of 48 patients, to whom the drug was administered in the single dose of 900 mg daily during the period of 3 months. In this paper we show the results of the treatment on five biochemical Coronary Heart Disease (CHD) risk variables: Cholesterol (CHOL), High Density Lipoprotein (HDL), Triglyccrides (TGL), Uric Acid (UA) and Glucose (GL). We are concerned with a statistical model allowing to predict which and how large changes in the considered variable can be expected in a patient taking the drug. This is done considering the “regression to the mean” effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text